Spectral Medical Inc.

EDT

CA8475771033

Pharmaceuticals

Market Closed - Toronto S.E. Other stock markets 01:19:58 31/05/2024 am IST			5-day change	1st Jan Change
0.47 ^CAD	-1.05%		-4.08%	+10.59%

30/05	Spectral Medical Closes C$8.5 Million Convertible Notes Financing	MT
30/05	Spectral Medical Inc. announced that it has received CAD 8.499564 million in funding	CI

Spectral Medical Inc Announces Retirement of Tony Businskas as Executive Vice President and CFO

October 18, 2017 at 05:30 pm IST

Spectral Medical Inc. announced that Tony Businskas will be retiring as the Executive Vice President and CFO of the company on January 31, 2018, after 12 years of service to the company. Tony joined Spectral in 2005 from his role as a senior VP and CFO for MDS Pharma Services and quickly became an important and key member of the senior management team.

Latest news about Spectral Medical Inc.

Spectral Medical Closes C$8.5 Million Convertible Notes Financing	30/05	MT
Spectral Medical Inc. announced that it has received CAD 8.499564 million in funding	30/05	CI
Spectral Medical Q1 Loss Widens, Says Tigris Trial Enrollment Reaches 106 Patients	13/05	MT
Spectral Medical Brief: Loss for the three-months ended March 31, 2024 was $4,160,000 ($0.01 per share)	13/05	MT
Spectral Medical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	13/05	CI
Spectral Medical Inc. announced that it expects to receive CAD 8.499564 million in funding	09/05	CI
Spectral Medical Says 105 Patients Now Enrolled in Tigris Trial	06/05	MT
Spectral Medical Brief: Providing April Tigris Trial Update; 105 patients enrolled; Says April represents a record breaking month for patient enrollment	06/05	MT
Spectral Medical Inc. Provides Tigris Trial Update	06/05	CI
Spectral Medical Updated on Tigris Trial	10/04	MT
Spectral Medical Brief: Providing Tigris Trial Update; 101 patients enrolled	10/04	MT
Spectral Medical Provides Tigris Trial Update	10/04	CI
North American Morning Briefing : Investors on -2-	05/04	DJ
Spectral Medical Brief: Paul Walker will immediately succeed Bihl as Chair	02/04	MT
Spectral Medical Brief: Anthony Bihl III, Spectral's Chairman, will be retiring from the Board at Upcoming Shareholder Meeting in June 2024	02/04	MT
Spectral Medical Inc. Announces Board Changes	02/04	CI
Spectral Medical Brief: Says Total of 97 patients randomized to date out of the 150 total patients to be enrolled in the Tigris trial	29/03	MT
Spectral Medical Brief: Q4 Revenue $365,000; Loss was $6,479,000, or $0.02 per share	29/03	MT
Spectral Medical Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03	CI
North American Morning Briefing : Stocks Struggle After New Records	22/03	DJ
Spectral Medical Provides February Tigris Trial Update	28/02	MT
Spectral Medical Inc. Provides Update on the Company's Tigris Trial	28/02	CI
Spectral Medical Brief: Providing February Tigris Trial Update; 93 patients enrolled; February represents a second record breaking consecutive month for patient enrollment	28/02	MT
Transcript : Spectral Medical Inc. - Special Call	22/02
Spectral Medical Says PMX Distribution and Supply Agreement with Baxter International Extended for 10 Years	22/02	MT

Chart Spectral Medical Inc.

Duration

Period

More charts

Company Profile

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Companyâs EAA. PMX has been on the market in many countries outside the United States and has been used in more than 340,000 patients to date. It is engaged in the development of biochemical markers for the clinical syndrome known as septic shock. It is also continuing its legacy business of manufacturing and selling certain reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.

Sector

Pharmaceuticals

Calendar

07/06/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.47 CAD

Average target price

1.8 CAD

Spread / Average Target

+282.98%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SPECTRAL MEDICAL INC.	+10.59%	9.62Cr
ELI LILLY AND COMPANY	+39.82%	73TCr
NOVO NORDISK A/S	+32.47%	59TCr
JOHNSON & JOHNSON	-7.31%	35TCr
MERCK & CO., INC.	+14.23%	32TCr
ABBVIE INC.	+0.86%	28TCr
ASTRAZENECA PLC	+13.92%	24TCr
ROCHE HOLDING AG	-6.50%	20TCr
NOVARTIS AG	+8.26%	21TCr
AMGEN INC.	+4.51%	16TCr

Other Pharmaceuticals